NantHealth Launches Genomic Proteomic Spectrometry Cancer Molecular Test
NantHealth has launched its Genomic Proteomic Spectrometry Cancer molecular test that measures the proteins in a patient’s tumor tissue.
The diagnostic features targeted quantitative proteomics with DNA and RNA sequencing, as well as a knowledge database with hundreds of oncogenes.
Results are available to physicians within 21 days in a report or through the GPS Cancer Genome Browser mobile application. — Michael Cipriano